Clinical Trial Search

Primary: Percentage Of Participants Achieving Alanine Aminotransferase Normalization — 31; 7; 56; 37 percentage of participants — p=0.0271

Primary: Myocardial Perfusion at Rest — 55; 135 IU/s

Primary: Percent Change in HDL-C From Baseline — 3.2; 84.2; 122.1; 160.6 percent change from baseline

Primary: Percent Change in Fasting Triglycerides From Baseline to 12 Weeks — 45.6; 3.7; -13.9 percent change — p=0.0538

Primary: Spleen Volume — 2324.0; 2120.0; 778.0; 1707.7 mL

Primary: Cholesteryl Ester Fractional Clearance Rate

Primary: Cholesterol Efflux Capacity (CEC) — 1.30; 0.65 Ratio

Primary: Percent Change From Baseline in Fasting TG at Month 6 — 11.52; -10.85; -31.99 percent change — p==0.0009

Primary: Number of LDLR Gene Mutations — 7 gene mutations

Primary: Change in Intestinal mRNA Expression Levels of LDL Receptor Between the Two 12-week Interventions — 110531; 95140 #copies/100000 copies housekeeping gene

Primary: Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs) — 109 Participants

Primary: Hepatic Triglyceride (%) — 15.9; 14.8 Fat/Fat+Water (%) — p=0.42

Primary: Change in Plasma Cholesterol — 37.8 change (%) compared to baseline — p=0.011

Primary: Body Composition — 39; 39; 37; 39 percentage

Primary: Absolute Change From Baseline to Month 3 in Fasting Triglycerides (TG) — -550.00 mg/dL

Primary: Percent Change in Plasma Low Density Lipoprotein-cholesterol (LDL-C) From Day 1 (Study Baseline) to Week 8. — 2.9; -3.7; -10.6 percent change from baseline — p=0.1122

Primary: Fecal Excretion of Plasma-derived Cholesterol — 1593; 1950 mg/day cholesterol excreted — p=0.019

Primary: Pharmacokinetics (PK) Parameters of Evacetrapib: Area Under the Concentration Versus Time Curve From Time Zero to the Last Time Point With a Measurable Concentration…

Primary: Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6 — -36.5; -49.6; -39.4; -53.9 Percent Change — p=<0.001

Primary: Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin…

Primary: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 — 17.6; -76.5 percent change — p=< 0.0001

Primary: Number of Responders — 18 Participants

Primary: Percent Change From Baseline in Fasting Serum Triglyceride (TG) at Month 10 — -85.7; -89.5; 38.8 Percent change — p=0.0022

Primary: Number of Participants Who Incurred at Least One Treatment Emergent Event — 33; 10 participants

Primary: Percent Change in LDL-C From Baseline to Week 12 — -25.25; -3.46 Percent Change — p=0.001

Primary: Hyperactivity Sub-scale of the Aberrant Behavior Checklist-Community (ABC-C). — 8.6; 8.6 units on a scale — p=1.0

Primary: Change in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12. — 0.978; 0.206; 0.270; 0.606 Ratio

Primary: Mean Percent Change From Baseline in Fasting Triglyceride (TG) — -59.8; -49.2; -64.9; -45.5 percent change

Primary: Change From Baseline in Urine 23S-Pentol During the Two Double-Blind Periods — 7.18; 6.96; 7.45; 10.34 natural log of ng/mL — p=<0.0001

Primary: Percent Change From Baseline in LDL-C at Week 12 — -16.03; -4.98 Percent Change — p=0.0057